234 related articles for article (PubMed ID: 22564397)
1. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center.
Lynch SP; Shen Y; Kamat A; Grossman HB; Shah JB; Millikan RE; Dinney CP; Siefker-Radtke A
Eur Urol; 2013 Aug; 64(2):307-13. PubMed ID: 22564397
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer.
Siefker-Radtke AO; Kamat AM; Grossman HB; Williams DL; Qiao W; Thall PF; Dinney CP; Millikan RE
J Clin Oncol; 2009 Jun; 27(16):2592-7. PubMed ID: 19414678
[TBL] [Abstract][Full Text] [Related]
3. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.
Porten S; Siefker-Radtke AO; Xiao L; Margulis V; Kamat AM; Wood CG; Jonasch E; Dinney CP; Matin SF
Cancer; 2014 Jun; 120(12):1794-9. PubMed ID: 24633966
[TBL] [Abstract][Full Text] [Related]
5. Oncologic outcomes following robot-assisted radical cystectomy with minimum 5-year follow-up: the Roswell Park cancer institute experience.
Raza SJ; Al-Daghmin A; Zhuo S; Mehboob Z; Wang K; Wilding G; Kauffman E; Guru KA
Eur Urol; 2014 Nov; 66(5):920-8. PubMed ID: 24768522
[TBL] [Abstract][Full Text] [Related]
6. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.
Metcalfe MJ; Ferguson JE; Li R; Xiao L; Guo CC; Czerniak BA; Siefker-Radtke A; Pretzsch SM; Navai N; McConkey DJ; Kamat AM; Campbell M; Dinney C
Eur Urol Focus; 2017 Dec; 3(6):577-583. PubMed ID: 28753816
[TBL] [Abstract][Full Text] [Related]
7. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study.
Hermans TJ; Fransen van de Putte EE; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; de Wit R; Beerepoot LV; Verhoeven RH; van Rhijn BW
Eur J Cancer; 2016 Dec; 69():1-8. PubMed ID: 27814469
[TBL] [Abstract][Full Text] [Related]
8. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.
Hautmann RE; de Petriconi RC; Pfeiffer C; Volkmer BG
Eur Urol; 2012 May; 61(5):1039-47. PubMed ID: 22381169
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation.
Zargar-Shoshtari K; Sverrisson EF; Sharma P; Gupta S; Poch MA; Pow-Sang JM; Spiess PE; Sexton WJ
Clin Genitourin Cancer; 2016 Feb; 14(1):82-8. PubMed ID: 26411593
[TBL] [Abstract][Full Text] [Related]
10. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
Krasnow RE; Drumm M; Roberts HJ; Niemierko A; Wu CL; Wu S; Zhang J; Heney NM; Wszolek MF; Blute ML; Feldman AS; Lee RJ; Zietman AL; Shipley WU; Efstathiou JA
Eur Urol; 2017 Jul; 72(1):54-60. PubMed ID: 28040351
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
13. [The prognostic value of adjuvant and neoadjuvant chemotherapy in total cystectomy for locally advanced bladder cancer].
Habuchi T; Kakehi Y; Terachi T; Ogawa O; Yoshida O
Nihon Hinyokika Gakkai Zasshi; 1999 Oct; 90(10):809-17. PubMed ID: 10565159
[TBL] [Abstract][Full Text] [Related]
14. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
[TBL] [Abstract][Full Text] [Related]
15. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05).
Lehmann J; Suttmann H; Albers P; Volkmer B; Gschwend JE; Fechner G; Spahn M; Heidenreich A; Odenthal A; Seif C; Nürnberg N; Wülfing C; Greb C; Kälble T; Grimm MO; Fieseler CF; Krege S; Retz M; Schulte-Baukloh H; Gerber M; Hack M; Kamradt J; Stöckle M
Eur Urol; 2009 Jun; 55(6):1293-9. PubMed ID: 19058907
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.
Li Q; Assel M; Benfante NE; Pietzak EJ; Herr HW; Donat M; Cha EK; Donahue TF; Bochner BH; Dalbagni G
Eur Urol Focus; 2019 Jan; 5(1):104-108. PubMed ID: 28753857
[TBL] [Abstract][Full Text] [Related]
17. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis.
Fajkovic H; Cha EK; Jeldres C; Robinson BD; Rink M; Xylinas E; Chromecki TF; Breinl E; Svatek RS; Donner G; Tagawa ST; Tilki D; Bastian PJ; Karakiewicz PI; Volkmer BG; Novara G; Joual A; Faison T; Sonpavde G; Daneshmand S; Lotan Y; Scherr DS; Shariat SF
Eur Urol; 2013 Nov; 64(5):837-45. PubMed ID: 22877503
[TBL] [Abstract][Full Text] [Related]
18. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
Cha EK; Shariat SF; Kormaksson M; Novara G; Chromecki TF; Scherr DS; Lotan Y; Raman JD; Kassouf W; Zigeuner R; Remzi M; Bensalah K; Weizer A; Kikuchi E; Bolenz C; Roscigno M; Koppie TM; Ng CK; Fritsche HM; Matsumoto K; Walton TJ; Ehdaie B; Tritschler S; Fajkovic H; Martínez-Salamanca JI; Pycha A; Langner C; Ficarra V; Patard JJ; Montorsi F; Wood CG; Karakiewicz PI; Margulis V
Eur Urol; 2012 Apr; 61(4):818-25. PubMed ID: 22284969
[TBL] [Abstract][Full Text] [Related]
19. Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy.
Simone G; Papalia R; Ferriero M; Guaglianone S; Castelli E; Collura D; Muto G; Gallucci M
Int J Urol; 2013 Apr; 20(4):390-7. PubMed ID: 22970939
[TBL] [Abstract][Full Text] [Related]
20. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]